Company news

Crinetics Pharmaceuticals, Inc. news in 2022

Crinetics Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Crinetics Pharmaceuticals Provides Update on CRN04777 Program

November 27, 2022

Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

November 21, 2022

Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 13, 2022

Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

October 12, 2022

Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism

October 5, 2022

Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer

October 2, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 11, 2022

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

September 7, 2022

New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism

September 1, 2022

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 11, 2022

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

August 3, 2022

Crinetics Presents Clinical and Research Results at ENDO 2022

June 7, 2022

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

June 6, 2022

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

May 24, 2022

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 11, 2022

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

April 17, 2022

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

April 11, 2022

Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts

March 29, 2022

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

March 29, 2022

Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer

March 20, 2022

Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors

March 13, 2022

Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer

February 28, 2022

Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan

February 27, 2022

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

February 8, 2022

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference

January 11, 2022

Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.

January 4, 2022

Calls in 2022

Decks in 2022